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Objectives: Human migration and concomitant HIV infections are likely to bring about major changes in the
epidemiology of some parasitic infections in Brazil. Human visceral leishmaniasis (HVL) control is particularly fraught
with intricacies. It is against a backdrop of decentralized health care that the complex HVL control initiatives are
brought to bear. This comprehensive review aims to explore the obstacles facing decentralized HVL control in
urban endemic areas in Brazil.
Method: A literature search was carried out in December 2015 by means of three databases: MEDLINE, Google
Scholar, and Web of Science.
Results: Although there have been many strides that have been made in elucidating the eco-epidemiology of
Leishmania infantum, which forms the underpinnings of the national control program, transmission risk factors for
HVL are still insufficiently elucidated in urban settings. Decentralized HVL epidemiological surveillance and control
for animal reservoirs and vectors may compromise sustainability. In addition, it may hamper timely human HVL
case management. With the burgeoning of the HIV-HVL co-infection, the potential human transmission may be
underestimated.
Conclusion: HVL is a disease with focal transmission at a critical juncture, which warrants that the bottlenecks
facing the control program within contexts of decentralized healthcare systems be taken into account. In addition,
HIV-driven HVL epidemics may substantially increase the transmission potential of the human reservoir. Calculating
the basic reproductive number to fine-tune interventions will have to take into consideration the specific socio-economic
development context.
Keywords: Human visceral leishmaniasis, HIV, Control and prevention, Decentralization, Human reservoir, Basic
reproductive number, Visceral leishmaniasis, HIV co-infectionBackground
Human visceral leishmaniasis (HVL) is endemic in 70
countries [1]. Leishmania infantum chagasi is the main
species causing HVL in Brazil. It is transmitted by sand-
flies, the species Lutzomyia longipalpis being the most
important HVL vector in the New World. The parasite
L. infantum multiplies within the sandfly for a period
between 8 and 20 days and, in humans, it has an* Correspondence: soniasimonemenon@gmail.com
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Brazil, canines are the main reservoirs [3], with humans
not considered necessary for maintaining transmission
within the community. A recent mathematical model
demonstrated that the insecticide-impregnated dog col-
lars and vector control [4] were the most effective inter-
ventions in reducing the prevalence of HVL in humans.
The HVL disease burden in Latin America is unknown
as most countries lack effective surveillance systems,
resulting in substantial underreporting [5–7], Brazil,
which harbors 90 % of the VL cases documented on the
American continent, [8] registered 70 thousand cases ofis distributed under the terms of the Creative Commons Attribution 4.0
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more than 3800 people [9, 10].
The typical manifestations of HVL include fever,
weight loss, hepatosplenomegaly, and pancytopenia
resulting from replication of Leishmania amastigotes in
macrophages mainly in the liver, spleen, and bone mar-
row, causing severe and ultimately lethal lesions [11].
Typical features such as splenomegaly may be absent in
VL-HIV-co-infected patients [12], whereas atypical
organ involvement, such as of the lungs or gastrointes-
tinal system and renal failure has been associated with
chronic VL in HIV patients [13–15]. Conversely, as
HIV viral load increases in patients with HIV-Leish-
mania co-infection [16], it promotes the clinical
progression of HIV and the development of AIDS-
defining conditions [17].
HVL was formerly restricted to rural areas in Brazil,
but since the 1980s, it has been spreading to urban cen-
ters. This spread has also lead to increasing numbers of
HIV co-infected cases [18], as HIV is also endemic in
urban centers in Brazil [19]. In 1988, Brazil adopted a
new federal constitution that called for a nationally
unified health system and facilitated the process of
municipalization. In this process, municipal govern-
ments, the smallest autonomous political and geographic
unit within the federal system, took on increasing levels
of resources and responsibility for a range of health and
other services, based in part on evaluations of their man-
agerial capacities [20].
From the 1950s to the end of the 1990s, the Brazilian
VL program was the responsibility of the federal govern-
ment. As result of the decentralization of the control
programs for epidemics, the control of leishmaniasis has
become the responsibility of the municipality [21, 22].
The decentralization of the program to the states and
municipalities has been implemented amidst difficulties
at these levels of governments, which have insufficient
accumulated experience in control [23]. Control pro-
grams over the past 20 years in Brazil have been accom-
panied by a substantial decentralization process [24],
which has been attributed to the successful control of
cholera, Chagas, and vaccine-preventable diseases [10]
but unsuccessful for certain vector-borne diseases in-
cluding HVL and dengue fever, both vector-borne
diseases with changing epidemiological profiles [10].
The objectives of this review were to highlight the
potential shortcomings of a HVL control program in a
decentralized context and to identify the clinical and
epidemiological research gaps for HVL control and
prevention.
Methods
A literature search was carried out in December 2015 by
means of three electronic databases: MEDLINE (1948-December 2015), Google Scholar, and Web of Science
(1899-December 2015). Papers in English and Portu-
guese were identified using medical subject headings
and truncations
Control of the animal reservoir and arthropod vector:
(visceral leishmaniasis OR Leishmania chagasi OR L
chagasi OR Kala-azar Leishmania infantum OR phlebo-
tomine sandflies) AND “Brazil” AND control.
Diagnosis of human VL: (visceral leishmaniasis OR
kala-azar OR L.infantum OR L. chagasi OR Leishmania
infantum OR Leishmania chagasiA ND (diagnostic
accuracy OR sensitivity OR specificity AND DAT OR
dipstick) AND “Brazil”
Treatment of human VL: For the PubMed search the
following key-words were used: (visceral leishmaniasis
L. chagasi AND treatment OR amphotericin B OR
Amphotericin B deoxycholate OR pentavalent antimo-
nials OR) AND (HIV positive OR AIDS) AND “Brazil”
Diagnosis of canine VL: (canine visceral leishmaniasis
OR L.infantum OR L.chagasi OR L.donovani OR Leish-
mania infantum OR Leishmania chagasi)AND (diagnos-
tic accuracy OR diagnostic performance OR sensitivity
OR specificity OR validation) AND “Brazil”
Decentralization of health care: (decentralization AND
vector-borne diseases) AND Brazil OR (decentralization
of health care AND Brazil)
An additional manual search was undertaken to in-
clude the bibliographies of the retrieved references.
Results
Epidemiology
Human visceral leishmaniasis (HVL) is a disease of pub-
lic health importance caused by protozoans belonging to
the genus Leishmania, which is present worldwide, par-
ticularly in Brazil, Bangladesh, India, Nepal, and Sudan
[25]. The humans, animal reservoir, and vector share the
same ecological niche, which contributes to the persist-
ence of the disease. There is a consensus that the control
of phlebotomine sandflies, the vector, is a daunting task
as the identification of their breeding sites is challenging,
which limits the effectiveness of control measures fo-
cused on immature forms of these vectors [26]. In Brazil,
sandflies have spread in both rural and urban area,
which contrasts with most other New World eco-
epidemiological situations where sandflies are associated
with forested areas.
Infectious dogs are considered the main reservoir and
are estimated to have a basic reproduction number (R0)
of 6, meaning that each infected dog gives rise to an
average of six new cases [27]. A study found that in the
city of Petrolina (State of Pernambuco, northeast region,
Brazil), of the 600 dogs tested, 19 % presented anti-L.
infantum antibodies [28]. The transmission of L. infan-
tum, which was restricted to rural areas and spread in
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concern and is the result of the environmental changes,
human disease reservoir migration, and adaptation of
the sandflies vector to the peri-domiciliary [29]. In the
last 20 years, despite the known underestimation of
cases, Brazil registered a marked increase in the inci-
dence of visceral leishmaniasis [27]. Whilst in the 1980s,
HVL was considered a rural disease, HVL has spread
throughout municipalities with 7 % of municipalities be-
ing endemic in 1985; 18 % in 1990; 30 % in 1996 and, in
2014, endemicity was reported in 21 of the 26 Brazilian
states plus the Federal District [30] and its control in
urban areas constitutes a challenge [31]. In the 1980s, an
average of 1500 cases was reported each year in Brazil,
and between 2000 and 2009, the average increased to
3480 cases annually, an increase of 132 % [32]. During
the period of 2002–2009, case fatality rate varied be-
tween 8.5 % in 2003 and 5.6 % in 2008, with an average
of 7.0 %, compared to 3.2 % in 1994 [33]. However, case
fatality rates derived from the national Database on
Reportable diseases (SINAN) are subject to an underre-
porting of 45.5 % [34] depending on the municipality, due
to deficiencies in access to health services and quality of
care along with atypical clinical manifestations [35].
Of the 44,289 cases reported in Brazil by SINAN dur-
ing 1980 to 2000, 89.9 % of these came from the north-
east. Among all the Federal states in Brazil, Maranhão, a
state in northeastern Brazil has recorded the highest
number of cases of HVL. Between 2000 and 2009, 5389
cases of HLV were registered, with the highest incidence
in the Regional health unit of Caxias, which reported
36.1 cases per 100,000 inhabitants [36].
In Northeastern Brazil, HIV has also become increas-
ingly prevalent [37]; however, information on co-infection
by VL and HIV in the northern region of Brazil is still
scarce [38]. HIV-HVL co-infection has become an emer-
ging public health issue [39]. The urbanization of HVL
has resulted in a geographical overlap between HVL and
AIDS in Brazilian inner cities [40].
Diagnostics
According to the Brazilian Ministry of Health, a diagno-
sis of HVL requires the identification of the parasite in a
smear or culture and/or positive serological testing in
patients presenting with fever and spleen enlargement
[41]. The once widely used serological test for HVL
diagnosis in Brazil immunofluorescence (IFI) [42], which
was typically performed in referral laboratories around
the country and required a delay of a few days to obtain
the results [43], has been replaced by the use of rapid
diagnostic tests (RDTs). This has been introduced to cir-
cumvent mortality by reducing diagnostic delay, as RDTs
have been shown to improve the early detection of HVL,
but their real-world performance in large urban settingsrequires additional study [34]. In Brazil, estimates of the
sensitivity and specificity of RDTs vary between 85.7 and
100 % and 82.0 and 100 %, respectively [44–47], al-
though only a few studies have been conducted outside
of controlled settings [48]. Additionally, RDTs have a
low sensitivity for HVL among HIV-infected patients,
estimated at 60 % (95 % CI 40.7–76.6 %). This low sensi-
tivity results in many undetected cases and therefore re-
quires invasive parasite detection to diagnose atypically
localized manifestations of VL [49]. The invasive nature
of the tests, including the parasitological demonstration
of the parasite in tissue smears requires considerable ex-
pertise [50] and carries the risk of potentially fatal bleed-
ing. Due to high treatment failure and the relapsing
nature of the disease, HIV-HVL patients are repeatedly
exposed to these tests.
Treatment
The first drug for the treatment of leishmaniasis is
pentavalent antimonial, which presents high toxicity and
exhibits a recurrence rate of 20 to 45 % [51–54]. The
immune deficiency caused by HIV facilitates the multi-
plication of the Leishmania parasite and further reduces
cure rates through conventional treatments [55–58]. In
addition, HIV-HVL have higher rates of drug toxicity,
higher mortality rates, resistance to pentavalent antim-
onial compounds, [59] and more relapses, especially if
CD4+ counts are <200 cells/μl, when compared with
HIV-negative VL patients [60]. The unfavorable out-
comes of co-infected patients prompted the Brazilian
Health Ministry to revise therapeutic guidelines in 2013
and recommended HIV co-infection as an indication for
therapy with liposomal amphotericin, which is more ex-
pensive and has a reduced toxicity as well as a high level
of efficacy with a 90 % cure rate [61]. Overlapping HIV
and HVL prevalence increases the risk of a HVL out-
break and possibly a drug-resistant one [62].
Concomitant HIV infection increases the risk of devel-
oping active HVL by between 100 and 230 times [63],
and AIDS also disproportionately affects the Brazilian
urban poor [64]. Coupled with the change in transmission
HVL pattern from the countryside to cities, this has led to
a surge of epidemic of L. infantum-HIV co-infections in
urban areas [65]. A recent ecological study identified
high-risk areas of human HVL cases, with most clinical
cases being among children and as opportunistic infec-
tions in HIV-infected patients [66] in the northern part of
Belo Horizonte, the capital of the state Minas Gerais. This
high-risk area also had a higher prevalence of poverty and
a higher number of infected dogs per inhabitants than
other parts of the city [67]. Moreover, as parasitemia is
frequent in HIV-HVL [68], co-infected patients may be
highly infectious to phlebotomine sandflies [69], leading
to increased HVL within the community.
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The Brazilian National System for Surveillance and
Control of Diseases is a decentralized, hierarchical, and
integrated network that uses a horizontal approach,
which attempts to reduce other vector-borne diseases
along with a broad-based participatory approach, as part
of the Unified Health System [70]. The backbone of the
national HVL Control and Surveillance Program is to re-
duce the morbidity and case fatality rates through early
diagnosis and treatment of human cases. Moreover, it
sets to curb the transmission risk by means of control-
ling the population of both domestic reservoirs and the
vector [71]. The program coordinates (i) vector popula-
tion control by means of residual insecticide spraying
and environmental management and (ii) culling of sero-
positive dogs in areas with moderate to high levels of
transmission [72]. This approach lies upon the assump-
tion that the incidence of L. infantum infection in
humans is directly related to the number of infectious
dogs and the vector capacity of the sandfly population to
transmit infection from dogs to humans [73]. Epidemio-
logical surveillance of HVL, insecticide spraying, and
dog culling control activities have been decentralized to
municipalities, which since 1994, have been given re-
sponsibility to plan and provide these services [74].
Program limitations
The decentralization program was initially successful in
putting in place a large-scale deployment of insecticide
spraying and dog culling [75]. However, the spread of
HVL to urban settings after more than 40 years of large-
scale deployment of insecticide spraying and dog culling
prompts an urgent revision of the Brazilian HVL control
program [76], since both strategies have obtained limited
results in interrupting transmission [61, 76, 77]. Since
the mid-eighties, studies have reported HVL in large
urban centers, including the southeastern metropolitan
areas of São Paulo [78], Rio de Janeiro [79], and Belo
Horizonte [80, 81] as well as in the northeastern capitals
of Teresina [74], São Luis [82, 83], and Fortaleza [84]. A
systematic review of studies conducted in Latin America
underscores the lack of scientific evidence to support
the effectiveness of such interventions [85], and also
highlights the need to address the lack of political com-
mitment, gaps in scientific knowledge, and poor case
management and surveillance systems [77].
The decentralization of epidemiological surveillance
and HVL control activities to the municipalities has
highlighted deficiencies in infrastructure at the local
level for addressing the complexity of HVL control [86].
A recent non-significant effect of insecticide spraying on
the incidence of human infection was determined for a
community randomized controlled trial in Teresina, the
capital of the Brazilian state of Piauí, in northeast Brazil.It illustrated how the shortage of available equipment
and trained personnel for large-scale spraying interven-
tions hampers the sustainability of control actions [69,
84, 87–90].
Although dog culling appears to have been effective in
reducing infection among humans in China [91], in
Brazil, where infectious dogs have been estimated to
have an R0 of approximately 6 [92], HVL has surged in
the past two decades despite the spraying of 200,000
houses and killing of 20,000 seropositive dogs per year
[93]. A mathematical model estimated that killing two
thirds of the infected dog population would result in less
than 20 % reduction in the incidence of human disease
[94]. Furthermore, immunofluorescence (IFI) antibody
tests commonly used for mass screening of dogs [95]
has low sensitivity and specificity [96], with estimates for
sensitivity ranging from 72 to 100 % and for specificity
from 52 to 100 % [84]. However, newer sensitive mo-
lecular diagnostic methods for canine visceral leishman-
iasis, like the conjunctival swab (CS) real-time PCR
reported that among the 1350 dogs screened, 369
(27.3 %) were positive by CS real-time PCR and 126
(9.3 %) tested positive by serological assays, which dem-
onstrate its potential as a mass screening tools in en-
demic settings to contribute to disease control [97].
A recent simulation study in Brazil indicated that very
low transmission settings (3 % prevalence), culling of
only symptomatic dogs, is sufficient to maintain
prevalence under 1 %. In higher endemicity settings
(R0 = 1.29, prevalence = 15 %) [98], removing clinically
diagnosed dogs, would be insufficient as a control
strategy given that the asymptomatic population of
dogs would be significant enough to maintain trans-
mission [75, 87, 99–101].
The failure of dog culling to reduce human cases may
also suggest the possibility of other reservoirs [102]. A
recent serological survey performed in Petrolina showed
that cats had a prevalence of 3.9 % of HVL [103].
Studies have shown that humans, crab-eating foxes,
opossums, domestic cats, and black rats can also trans-
mit L. infantum to sandflies; nevertheless, their import-
ance is deemed to be minimal [77]. However, in certain
scenarios these secondary reservoirs would be capable of
sustaining transmission, which would warrant further
studies on their transmission potential [104].
HVL clinical management within a decentralized context
The decentralization of health care to the municipality
level also has had an impact on the early detection and
effective clinical management of HVL. A study in north-
western Paraná State revealed that both early treatment
initiation and clinical evaluation were more complete
with a centralized healthcare system than with a decen-
tralized one [105]. After the decentralization, 32 % of
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antimonial, and were treated without compliance to the
recommended dosage of 30 days at 20 mg/kg/day [106].
Furthermore, 73 % of patients in the study were noted
to having received inadequate treatment, and 84 % of
patients failed to receive proper clinical follow-up [106].
The lack of rigorous clinical management ensuing
decentralization may have an even more profound effect
for clinical management of co-infection HIV-HVL, in
whom HVL appears in atypical forms and is more diffi-
cult to diagnose [107].Knowledge gaps
Active surveillance
The cost effectiveness of implementing an active surveil-
lance system to detect HVL cases in endemic urban
areas needs to be evaluated. Active surveillance in urban
areas would entail involving community health workers
in active case finding in the community in order to de-
tect those patients who may not seek treatment in health
facilities so that a more prompt treatment is initiated;
this could be done through the use of RDT. Active case
finding would enable more accurate estimates of HVL in
urban areas to allow a better understanding of the actual
burden. Additionally, active case finding would provide
the data needed to the reliable estimates of HIV-HVL
co-infection, which is currently lacking in northeast
Brazil. In 2012, HIV-HVL co-infection prevalence was
8.5 % of all HVL cases [108]; however, there are likely a
significant number of asymptomatic co-infected individ-
uals which are undetected [109, 110]. The use of differ-
ent diagnostic tests for active surveillance should also be
evaluated, to understand the health and cost implica-
tions of differing technologies.Identification of other potential reservoirs and
transmission risk factors
In zoonotic disease control, early diagnosis and treat-
ment is essential for the patient, but is believed to have
limited impact on transmission if the main animal reser-
voir or insect vectors are not targeted [111]. In Brazil,
transmission risk factors for HVL are still insufficiently
elucidated, notably in urban and densely populated areas
[112]. The transmission potential by asymptomatic ca-
nine as well as the identification of other potential reser-
voirs needs to be determined. In the Indian continent,
mathematical modeling has suggested that Leishmania
donovani in asymptomatic individuals may also be an
instrumental in maintaining transmission in endemic
communities [113]. Mathematical modeling is also
needed to determine whether L. infantum in asymptom-
atic individuals are also instrumental in maintaining
transmission in endemic communities.Effectiveness of interventions
A systematic review of studies conducted in Latin
America underscores the lack of scientific evidence to
support the effectiveness of such interventions [84], and
also highlights the need to address the lack of political
commitment, gaps in scientific knowledge, and poor
case management and surveillance systems [72]. Regular
monitoring of human, vector, and reservoir VL at muni-
cipality level is vital to guide and tailor the HVL control
strategy in urban centers.
Impact of the decentralization on HVL surveillance and
control interventions
There is limited research on the impact of decentralization
on HVL surveillance, sandfly control, dog culling, culling
of seropositive dogs, and case management. There should
be a comprehensive review, which will identify the
deficiencies in the system, such as bottlenecks in ser-
vice provision or resources to appropriate implement
a program.
HIV-related gaps
Clinical management of HIV-HVL co-infection in Brazil
The recommendation to treat HIV-infected patients with
amphotericin B was based on the opinion of experts and
from clinical trials mostly conducted in India [114]. In
East Africa, cure rates have had limited results, with
56 % of VL relapse cases demonstrating parasitological
failure in Northern Ethiopia [115], and in Mediterranean
countries [116]. Its efficacy in Brazil has yet to be estab-
lished, and this recommendation should be further ex-
amined in the Brazilian context.
Impact of HAART on HVL clinical management
HVL relapses have been shown to occur in patients on
highly active antiretroviral therapy (HAART), despite
increasing CD4+ counts and undetectable HIV loads
[117, 118]. Moreover, HVL also seems to hamper the
immunological recovery of the HIV-positive patients
treated with HAART [119]. It remains to be investigated
whether earlier CD4 count initiation may prevent HVL
relapses.
Impact of HAART on drug-resistant HVL
In light of potential HIV-driven drug-resistant HVL out-
breaks [120], the prevalence of drug-resistant HVL in
HIV-infected persons and immuno-epidemiological pa-
rameters should be determined. Moreover, the impact of
earlier HAART initiation on preventing drug-resistant
transmission should be HVL explored.
Impact of HAART on the human reservoir
HAART may also lead to asymptomatic carriers [121,
122] and these may pose a risk for transmission in areas
Menon et al. Tropical Medicine and Health  (2016) 44:9 Page 6 of 9where the sandfly vector is present [123]. Research will
need to be conducted to assess how changes in the
HAART landscape, such as the WHO 2013 recommen-
dation to initiate treatment at CD4 >350 count [124],
may contribute to maintaining transmission in endemic
communities.
Conclusions
There is evidence that suggests the current practices of
HVL control in Brazil have not been effective at control-
ling the spread of HVL. The lack of control effectiveness
may be attributed to deficiencies in infrastructure at the
local level for addressing the complexity of HVL control,
in addition to the decentralization of health care to the
municipality level, as well as clinical and epidemiological
knowledge gaps.
Whilst decentralization of health care in Brazil has en-
hanced community participation [125], early diagnosis
and treatment of human cases has also been impacted
negatively by decentralization, with poor adherence of
the standard treatment being reported in first-line treat-
ment in resource-poor municipalities. Municipalities
may lack the high level of clinical expertise to deal with
the challenges that HIV-HVL co-infection management
entail. These include suboptimal sensitivity of point of
point-of-care diagnostics that require reliance on more
invasive tests for monitoring lower cure rates, higher
drug toxicity, drug interaction with HAART, relapse and
mortality rates than those without HIV [126].
With cases of HIV-HVL co-infection burgeoning, the
human transmission potential may be underestimated.
As HIV disproportionately affects the Brazilian urban
poor [127], who in turn are more at risk of living in poor
municipalities and being co-infected with HVL, poor
municipalities may fuel both a HIV-HVL epidemic and
drug-resistant HVL transmission.
HVL should be considered as a disease with focal
transmission [107], in which the conditions for transmis-
sion depend on local socio-economic factors. Despite
the milestones in the HVL and in the canine HVL diag-
nostic landscape, which would enable rapid diagnoses at
local level, a balance must be drawn between govern-
ment and community involvement for control initiatives
if local HVL control programs are to be sustained.
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